TTYP01 Tablets (12mg or 18mg) for autism spectrum disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jan 2025: Trial registered, NCT06757504
  2. 13 Jan 2025: Trial started, NCT06757504

The trials

NCT06757504: Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

State
Under way
Phase
Phase 2
People
150 planned
Started
13 Jan 2025
Primary completion
6 Feb 2026
Arms
TTYP01 low-dose group, TTYP01 high-dose group
Results
None posted
  1. 3 Jan 2025: Trial registered
  2. 13 Jan 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.